Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
Nature Communications
|
July 17, 2021
Self-rechargeable cardiac pacemaker system with triboelectric nanogenerators
Hanjun Ryu, Hyun-Moon Park, Moo-Kang Kim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 21, 2011
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma
Tae-Ho Hwang, Anne Moon, James Burke, et al.
Science Translational Medicine
|
May 17, 2013
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans
Mi Kyung Kim, Caroline J Breitbach, Anne Moon, et al.
Cancer Research and Treatment
|
December 19, 2015
Gene Expression Profiling of Non-Small Cell Lung Cancer
Mee Sook Roh, Hyuk Chan Kwon, Jin Sook Jeong, et al.
Biomedicines
|
October 21, 2020
Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase
S M Bakhtiar Ul Islam, Young Mi Hong, Mefotse Saha Cyrelle Ornella, et al.
Current Pharmaceutical Design
|
February 26, 2019
10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein
Dong-Hwan Lee, Md Hasanuzzaman, Daeho Kwon, et al.
Experimental & Molecular Medicine
|
February 9, 2013
Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells
Sung Nam Park, Kyung Tae Noh, Young-Il Jeong, et al.
Iscience
|
March 8, 2024
Development of chimeric antigen receptor (CAR)-T cells targeting A56 viral protein implanted by oncolytic virus
Euna Cho, Min Ho An, Yi Sle Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 23, 2014
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients
Timothy P Cripe, Minhtran C Ngo, James I Geller, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
June 16, 2015
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Se Hoon Park, Caroline J Breitbach, Jeeyun Lee, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
Nature Communications
|
July 17, 2021
Self-rechargeable cardiac pacemaker system with triboelectric nanogenerators
Hanjun Ryu, Hyun-Moon Park, Moo-Kang Kim, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
July 21, 2011
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma
Tae-Ho Hwang, Anne Moon, James Burke, et al.
Science Translational Medicine
|
May 17, 2013
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans
Mi Kyung Kim, Caroline J Breitbach, Anne Moon, et al.
Cancer Research and Treatment
|
December 19, 2015
Gene Expression Profiling of Non-Small Cell Lung Cancer
Mee Sook Roh, Hyuk Chan Kwon, Jin Sook Jeong, et al.
Biomedicines
|
October 21, 2020
Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase
S M Bakhtiar Ul Islam, Young Mi Hong, Mefotse Saha Cyrelle Ornella, et al.
Current Pharmaceutical Design
|
February 26, 2019
10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein
Dong-Hwan Lee, Md Hasanuzzaman, Daeho Kwon, et al.
Experimental & Molecular Medicine
|
February 9, 2013
Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells
Sung Nam Park, Kyung Tae Noh, Young-Il Jeong, et al.
Iscience
|
March 8, 2024
Development of chimeric antigen receptor (CAR)-T cells targeting A56 viral protein implanted by oncolytic virus
Euna Cho, Min Ho An, Yi Sle Lee, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 23, 2014
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients
Timothy P Cripe, Minhtran C Ngo, James I Geller, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
June 16, 2015
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer
Se Hoon Park, Caroline J Breitbach, Jeeyun Lee, et al.
Page
of 6